Semaglutide reduces kidney damage and progression in patients with type 2 diabetes and chronic kidney disease independently of weight loss, and its effect on albuminuria is consistent regardless of concomitant mineralocorticoid receptor antagonist use.

Study: Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis

Semaglutide helped protect kidneys in diabetic patients with kidney disease, whether or not they were also taking another kidney medication — meaning semaglutide works on its own, not just because it helps people lose weight.

Study: Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial

This study found that a diabetes drug called semaglutide helped slow down kidney damage in people with diabetes and kidney disease, even without considering weight loss. It didn’t test every detail, but the main idea that it protects kidneys looks true.

Study: The Role of GLP-1 Receptor Agonists (Ozempic and Mounjaro) as Secondary Therapy in Chronic Kidney Disease

This study found that semaglutide helps protect kidneys in diabetic patients, even if they lose weight, and reduces a key marker of kidney damage called albuminuria. It doesn’t say whether other kidney meds change this effect, but the main benefits are clear.

Study: #2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial

Semaglutide helped protect kidneys in overweight people with heart disease, even without them losing weight, and it lowered a key marker of kidney damage no matter how bad their kidney condition was to start with.